Brachytherapy rather than surgery is a good option for cancer of the penis

May 8, 2017

Results from the largest group of men treated for cancer of the penis by a single institution have shown that treatment with brachytherapy (a type of radiotherapy) is a good option that can be used instead of surgery in many cases.

The study was presented at the ESTRO 36 conference and is important because penile is extremely rare - less than one man in 100,000 is affected in developed countries, although there is a higher incidence in developing countries - and so it is difficult to gather enough evidence to show that one type of is better than another. The most frequent treatment is surgery to remove the glans (the tissue at the end of the penis), but this has an obvious impact on a man's sexual and urinary functioning.

Dr Alexandre Escande, a resident in radiation oncology at the Gustave Roussy Cancer Campus (Villejuif, France), and his colleagues examined the outcomes of 201 men, aged over 45, treated at their institution and followed up for several years until March 2016 (median average follow-up time was 10.7 years). All the men were circumcised and then treated with , which involved inserting radioactive wires in or near the tumour; these emit radiation at a low dose rate for several days, delivering a total dose of between 36.5 and 76 Gy to kill the cancer cells.

Five years after treatment the probability of surviving with the penis intact was 85%, although 13 men (6%) had surgical treatment for toxic side effects of the treatment, such as painful ulcerations. The overall survival rate was 79% and the rate for surviving without the cancer recurring was 82%. Eight men (4%) had to have their penises removed by surgery and 18 men (13%) had partial surgery after their cancer returned.

Men who did less well and were more likely to suffer a recurrence of their cancer and to require further treatment, including surgery, were those whose cancer had started to metastasise (spread) to the lymph nodes in the groin, who had tumours larger than 4cms in diameter, or who were treated with brachytherapy at a dose less than 62 Gy. Neutrophilia (a high white blood cell count) at the time of diagnosis was linked to a higher risk of metastasis.

Dr Escande told the conference: "These results show that brachytherapy is the treatment of choice for selected patients whose cancer has not spread into the sponge-like regions of the erectile tissue in the penis - the corpus cavernosum. It is effective at controlling and eradicating the cancer and allows a high number of men to preserve their penises.

"Another important finding was that if cancer did return, then this could often be dealt with successfully by a second round of brachytherapy or by without the men being at higher risk of death from the disease. This suggests that brachytherapy is an adequate upfront, organ-sparing strategy, which is usually associated with only mild to moderate toxicities. Men still have a good body image, and also sexual and urinary function for the majority."

President of ESTRO, Professor Yolande Lievens, head of the department of at Ghent University Hospital, Belgium, said: "These are very encouraging results from an excellent study of a large group of men with a rare cancer who were followed up for a long period of time. These findings further endorse the important role of radiotherapy -brachytherapy in this particular situation - in organ-sparing curative approaches to cancer. The use of brachytherapy in this very rare cancer type not only translated into high survival rates of men with this disease, but also ensured that the impact on their quality of life was kept to a minimum."

Explore further: Giving a single, high dose of radiation directly to the site of a prostate tumor is safe

More information: Abstract no: OC-0466, "Highlights of proffered papers" session at 11.50-12.30 hrs (CEST) on Monday, 8 May, Auditorium. The 36th annual congress of the European SocieTy for Radiotherapy & Oncology.

Related Stories

Giving a single, high dose of radiation directly to the site of a prostate tumor is safe

May 6, 2017
Doctors have found that treating prostate cancer with a single, high dose of radiation delivered precisely to the site of the tumour results in good quality of life and fewer trips to the hospital, with adverse side effects ...

ASCO and Cancer Care Ontario update guideline on radiation therapy for prostate cancer

March 28, 2017
The American Society of Clinical Oncology (ASCO) and Cancer Care Ontario today issued a joint clinical practice guideline update on brachytherapy (internal radiation) for patients with prostate cancer. The update provides ...

Cervical cancer survivors suffer from fatigue, insomnia and hot flushes

May 4, 2017
Around half of women who have been treated for locally advanced cervical cancer suffer from symptoms of insomnia, fatigue or hot flushes at some point, according to new research presented at the ESTRO 36 conference.

Type of treatment for prostate cancer affects quality of life

April 20, 2017
Quality of life after prostate cancer treatment varies by the type of treatment patients receive, a new study reveals.

New insights into side effects can help prostate cancer patients choose treatments

March 21, 2017
For many men newly diagnosed with early-stage prostate cancer, concerns about potential quality-of-life issues often guide treatment decisions. A new study led by UNC Lineberger Comprehensive Cancer Center researchers identifies ...

Brachytherapy improves survival for inoperable early stage endometrial cancer

April 25, 2015
Women who have early stage endometrial cancer and are inoperable tend to live longer if they have been treated with brachytherapy with or without external beam radiation, according to new research to be presented at the 3rd ...

Recommended for you

CAR-T immunotherapy may help blood cancer patients who don't respond to standard treatments

October 20, 2017
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis is one of the first centers nationwide to offer a new immunotherapy that targets certain blood cancers. Newly approved ...

Researchers pinpoint causes for spike in breast cancer genetic testing

October 20, 2017
A sharp rise in the number of women seeking BRCA genetic testing to evaluate their risk of developing breast cancer was driven by multiple factors, including celebrity endorsement, according to researchers at the University ...

Suicide molecules kill any cancer cell

October 19, 2017
Small RNA molecules originally developed as a tool to study gene function trigger a mechanism hidden in every cell that forces the cell to commit suicide, reports a new Northwestern Medicine study, the first to identify molecules ...

Fundamental research enhances understanding of major cancer gene

October 19, 2017
New research represents a promising step towards better understanding of a key cancer gene. A long-running collaboration between researchers at the Babraham Institute, Cambridge and the AstraZeneca IMED Biotech Unit reveals ...

Study shows how nerves drive prostate cancer

October 19, 2017
In a study in today's issue of Science, researchers at Albert Einstein College of Medicine, part of Montefiore Medicine, report that certain nerves sustain prostate cancer growth by triggering a switch that causes tumor vessels ...

Gene circuit switches on inside cancer cells, triggers immune attack

October 19, 2017
Researchers at MIT have developed a synthetic gene circuit that triggers the body's immune system to attack cancers when it detects signs of the disease.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.